Peel Hunt reiterated their hold rating on shares of Abcam (LON:ABC) in a research note released on Thursday.
Other research analysts also recently issued research reports about the company. Berenberg Bank upgraded Abcam to a buy rating and boosted their target price for the company from GBX 1,230 ($16.07) to GBX 1,640 ($21.43) in a research note on Tuesday, July 31st. Numis Securities restated a hold rating and issued a GBX 1,380 ($18.03) target price on shares of Abcam in a research note on Thursday, July 12th.
Shares of ABC stock opened at GBX 1,243 ($16.24) on Thursday. Abcam has a 1-year low of GBX 9.73 ($0.13) and a 1-year high of GBX 1,290 ($16.86).
The company also recently announced a dividend, which will be paid on Friday, November 30th. Shareholders of record on Thursday, November 8th will be paid a GBX 8.58 ($0.11) dividend. The ex-dividend date of this dividend is Thursday, November 8th. This represents a yield of 0.65%. This is an increase from Abcam’s previous dividend of $3.42.
In other Abcam news, insider Jonathan Simon Milner sold 1,000,000 shares of the business’s stock in a transaction dated Friday, September 28th. The stock was sold at an average price of GBX 1,441 ($18.83), for a total value of £14,410,000 ($18,829,217.30). Also, insider Peter Allen bought 12,000 shares of the stock in a transaction on Thursday, September 13th. The stock was purchased at an average price of GBX 1,304 ($17.04) per share, for a total transaction of £156,480 ($204,468.84).
Abcam Company Profile
Abcam plc, together with its subsidiaries, produces and distributes research-grade antibodies and associated protein research tools worldwide. The company primarily offers primary and secondary antibodies; ELISA, matched antibody pairs and multiplex immunoassays; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex miRNA assays.
See Also: Trading Strategy Examples and Plans
Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.